S&P 500   3,002.38 (+0.54%)
DOW   26,798.97 (+0.11%)
QQQ   193.12 (+0.75%)
AAPL   240.84 (+1.87%)
FB   189.22 (+1.81%)
MSFT   137.74 (+0.24%)
GOOGL   1,246.08 (+0.13%)
AMZN   1,779.51 (+1.25%)
MU   45.00 (+3.52%)
AMD   32.09 (+3.62%)
T   38.41 (-0.16%)
F   9.10 (-2.04%)
BAC   31.13 (+2.57%)
GILD   65.08 (+0.26%)
DIS   130.84 (-0.04%)
S&P 500   3,002.38 (+0.54%)
DOW   26,798.97 (+0.11%)
QQQ   193.12 (+0.75%)
AAPL   240.84 (+1.87%)
FB   189.22 (+1.81%)
MSFT   137.74 (+0.24%)
GOOGL   1,246.08 (+0.13%)
AMZN   1,779.51 (+1.25%)
MU   45.00 (+3.52%)
AMD   32.09 (+3.62%)
T   38.41 (-0.16%)
F   9.10 (-2.04%)
BAC   31.13 (+2.57%)
GILD   65.08 (+0.26%)
DIS   130.84 (-0.04%)
Log in

Ritter Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RTTR)

$0.29
0.00 (0.00 %)
(As of 10/21/2019 12:19 PM ET)
Today's Range
$0.28
Now: $0.29
$0.31
50-Day Range
$0.24
MA: $0.52
$1.21
52-Week Range
$0.23
Now: $0.29
$1.85
Volume150,382 shs
Average Volume1.82 million shs
Market Capitalization$2.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTTR
CUSIPN/A
Phone310-203-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.22 per share

Profitability

Net Income$-16,870,000.00

Miscellaneous

Employees7
Market Cap$2.76 million
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable

Receive RTTR News and Ratings via Email

Sign-up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.


Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?

Shares of Ritter Pharmaceuticals reverse split on the morning of Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) announced its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.18. View Ritter Pharmaceuticals' Earnings History.

When is Ritter Pharmaceuticals' next earnings date?

Ritter Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Ritter Pharmaceuticals.

What is the consensus analysts' recommendation for Ritter Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ritter Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ritter Pharmaceuticals.

Has Ritter Pharmaceuticals been receiving favorable news coverage?

News coverage about RTTR stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ritter Pharmaceuticals earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Ritter Pharmaceuticals.

Are investors shorting Ritter Pharmaceuticals?

Ritter Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 492,000 shares, an increase of 36.1% from the August 30th total of 361,500 shares. Based on an average trading volume of 869,400 shares, the short-interest ratio is currently 0.6 days. Currently, 5.8% of the company's shares are sold short. View Ritter Pharmaceuticals' Current Options Chain.

Who are some of Ritter Pharmaceuticals' key competitors?

What other stocks do shareholders of Ritter Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Apache (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and CARBO Ceramics (CRR).

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the folowing people:
  • Mr. Ira Eliot Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 70)
  • Mr. Andrew J. Ritter, Co-Founder, CEO, Pres, Corp. Sec. & Director (Age 36)
  • Mr. Michael D. Step, Consultant & Director (Age 59)
  • Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 59)
  • Ms. Ellen F. Mochizuki, Consultant (Age 52)

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager.

How do I buy shares of Ritter Pharmaceuticals?

Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of RTTR stock can currently be purchased for approximately $0.29.

How big of a company is Ritter Pharmaceuticals?

Ritter Pharmaceuticals has a market capitalization of $2.73 million. The biotechnology company earns $-16,870,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Ritter Pharmaceuticals employs 7 workers across the globe.View Additional Information About Ritter Pharmaceuticals.

What is Ritter Pharmaceuticals' official website?

The official website for Ritter Pharmaceuticals is http://www.ritterpharmaceuticals.com/.

How can I contact Ritter Pharmaceuticals?

Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]


MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  476
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe RTTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel